What are the recommended treatment protocols for Helicobacter pylori infection in adults?

H. Pylori Treatment Protocols

For treatment-naive adults with H. pylori infection, bismuth quadruple therapy (BQT) for 14 days is the preferred first-line regimen when antibiotic susceptibility is unknown. 1

First-Line Treatment Options

Preferred Empiric Regimen

• Bismuth quadruple therapy (14 days): Bismuth ~300mg four times daily + metronidazole 500mg three times daily + tetracycline 500mg four times daily + PPI twice daily 2, 1
  • This regimen achieves >90% eradication rates in most geographic areas 2
  • Should be taken with meals for the combination tablets, with PPI 30 minutes before meals and at bedtime 2

Alternative First-Line Regimens (When BQT Not Available)

• Rifabutin triple therapy (14 days): Rifabutin 150mg twice daily + amoxicillin 1g three times daily + high-dose PPI (esomeprazole or rabeprazole 40mg) twice daily 2, 1

  • Resistance to rifabutin and amoxicillin is rare (<15%), making this reasonable without susceptibility testing 2
  • FDA-approved formulation (Talicia®) is available 2

• Concomitant therapy (14 days): Clarithromycin 500mg twice daily + amoxicillin 1g twice daily + metronidazole 500mg twice daily + PPI twice daily 2, 3

  • Only use in areas with clarithromycin resistance <15% 2, 3

Critical PPI Selection

Use high-potency PPIs (esomeprazole 20-40mg or rabeprazole 20-40mg twice daily) and avoid pantoprazole, as PPI potency significantly impacts eradication success with amoxicillin-containing regimens 2

• Relative potency: 20mg rabeprazole = 36mg omeprazole; 20mg esomeprazole = 32mg omeprazole; 40mg pantoprazole = only 9mg omeprazole 2

Second-Line Treatment (After First Failure)

For Patients Who Failed Non-BQT First-Line Therapy

• "Optimized" bismuth quadruple therapy (14 days) using the regimen above with high-dose PPI 1

For Patients Who Failed Optimized BQT

• Rifabutin triple therapy (14 days) as described above 1

Alternative Second-Line Options

• Tetracycline-levofloxacin quadruple therapy: PPI + bismuth + tetracycline + levofloxacin 500mg daily 4

  • Achieves 98% per-protocol eradication rate versus 69% for levofloxacin-amoxicillin triple therapy 4
  • Superior to standard levofloxacin triple therapy due to rising fluoroquinolone resistance 4

• High-dose dual therapy (14 days): Amoxicillin 2-3g daily in 3-4 divided doses + high-dose PPI twice daily 2, 4

  • Achieves 89% eradication rate in second-line treatment 4

Third-Line and Salvage Therapy

After Two Failed Regimens

Obtain antibiotic susceptibility testing before selecting further treatment 2, 1

• Clarithromycin-based or levofloxacin-based regimens should only be used if susceptibility is confirmed 2, 1

Salvage Options (Based on Susceptibility)

• Rifabutin triple therapy (if not previously used) 2
• Levofloxacin quadruple therapy (only if susceptibility confirmed) 2
• High-dose dual therapy 2

Rifabutin regimens should be restricted to patients who have failed ≥3 prior treatment attempts 3

Critical Treatment Principles

Duration

All H. pylori eradication regimens must be given for 14 days 2, 3

• The consensus strongly recommends against shorter durations due to increasing treatment failure 3

Obsolete Therapies to Avoid

The following regimens are now considered obsolete and should not be used: 2

• Sequential therapy
• Hybrid therapy
• Reverse hybrid therapy
• Concomitant therapies that include antibiotics offering no therapeutic benefit

Common Pitfalls

• Do not use clarithromycin triple therapy empirically unless local resistance is documented <15% or local eradication success is >90% 2, 3
• Avoid pantoprazole in amoxicillin-containing regimens due to inferior potency 2
• Do not use fluoroquinolones as first-line therapy - FDA recommends these as last choice due to serious side effects 2
• Ensure patient adherence is confirmed before declaring treatment failure 2

Post-Treatment Testing

Universal test-of-cure is recommended after treatment, though specific timing should follow local protocols 1

• Testing rates remain suboptimal (only 50-64% of patients receive eradication testing) 5

Local Resistance Patterns

Compile and utilize local eradication success rate data for each regimen to guide therapy selection 2

• Aggregated data should be publicly available to inform clinical decisions 2
• The goal is to achieve ≥95% cure rates, with minimum acceptable threshold of 90% 2